Connective Orthopaedics Wants to Improve ACL Surgeries, Taps Boston Celtics CEO as Director

Sports fans know how a knee injury ruined the last season for beloved New England Patriots quarterback Tom Brady, and many other athletes before him. Now Connective Orthopaedics , a Waltham, MA, medical devices startup, is quietly researching new products that could potentially improve recoveries for people after they undergo knee surgery.

Connective CEO Dean Banks told me that the vision of the company is to eventually provide products that help torn ACLs (short for anterior cruciate ligaments) in the knee to heal themselves, as opposed to the standard treatment of replacing the damaged ligaments with tissue taken from other parts of a patient’s body or from a donor source. The startup has been attracting attention in the sports world by adding Boston Celtics CEO Wyc Grousbeck to its board of directors in June. (It turns out that Connective’s Banks and the Celtics’ Grousbeck go way back—they used to work together at Highland Capital Partners in Lexington, MA.)

Banks declined to give specifics about his company’s technology, but he showed me a recently published study to give me an idea. The study indicated that pigs that had reconstructed ACLs that were wrapped in a collagen-platelet scaffold healed back to normal better than the pigs that went without the scaffolds to help mend their ACLs after reconstructive surgery. Collagen is the ubiquitous protein that supports organ structure in the body, and platelets are blood cells that contain growth-stimulating proteins. Though Connective isn’t saying whether it’s developing a collagen-platelet product, the firm is clear that it wants to develop products that promote tissue healing. The secrecy is one indication of the fierce competition Connective is facing.

“We are really, really intent on staying in stealth mode because if you look at the potential of the company it’s extraordinary,” Banks said, “but I’ve seen some evidence that there’s a lot of interest in these markets and there are a lot of large players.”

Because Banks sent me collagen-platelet study, which was published in a recent issue of the American Journal of Sports Medicine, I’m led to believe that it’s quite possible that Connective’s experimental product is a close match to the scaffold in the study. The lead investigator of the study, Brown University professor Braden Fleming, is a scientific advisor to the company. Also, the company’s scientific founders—Children’s Hospital Boston orthopedic surgeon Martha Murray and Vanderbilt University Medical School orthopedics professor Kurt Spindler—also participated in the research. Connective licensed its technology from Children’s Hospital and Vanderbilt. Yet even the company’s website makes no mention of platelet-collagen technology.

There are some large companies interested in using collagen to improve tissue repair. Locally, Organogenesis produces patches that use collagen from pigs. The Canton, MA-based firm has a collagen-based scaffold for use in tendon repair that was developed with major orthopedic products maker Biomet, headquartered in Warsaw, IN. (Collagen is useful to improve healing because it can support re-growth of tissue, according to Organogenesis.) Those are just a couple of the firms out there that could be considered Connective’s competition in providing products laced with biological materials to promote soft tissue healing. But Banks said he doesn’t consider those companies competition at this point because his firm has a unique (albeit secret) product to offer.

Banks also wanted to keep secret the firm’s timeline for conducting human clinical trials and launching its first product onto the market. But he did tell me that his company has raised $4 million in early funding from Waltham-based Norwich Ventures, which focuses on making investments in medical devices firms. (In fact, Aaron Sandoski, chairman of Connective and managing director at Norwich, introduced me to Banks back in June.)

Banks and I talked quite a bit about ligament reconstruction, though, and the opportunities to improve how well people recover from ACL injuries. For starters, ACLs connect our thighbones to our shinbones, putting them in harms way when football players are tackled at or below the knees (just ask Tom Brady.) As mentioned, the standard approach to address ACL injuries is ACL reconstruction, which involves surgery to remove the damaged ligament and replace it with tissue taken from another part of the patient’s own knee, hamstring, or from an outside source such as a human cadaver. Here’s a link to a pretty good description of how arthroscopic ACL reconstruction is done.

According to the National Institutes of Health, ACL reconstruction is typically a very successful surgery. Yet in some cases the repaired knee is weaker than before or can’t move with the same freedom as it could prior to the surgery. Banks said that patients who undergo these surgeries are also more likely to develop osteoarthritis in their knees, and his company hopes to someday provide a product to remedy that problem and others.

Trending on Xconomy

By posting a comment, you agree to our terms and conditions.

Comments are closed.